The experimental effects of prostaglandin E1 on small vessel patency

  • Roderick G. Lamond
  • Norman L. Chater


In the hands of skilled microsurgeons a patency rate close to 90% can be expected in the surgical anastomosis of 1.0-mm vessels. Considering today’s instruments and techniques, however, if microsurgery is to progress to areas of new application (such as an occipital artery-posterior fossa bypass) several factors need to be overcome, one of the more important ones being consistent patency rates in vessels of 0.5-mm diameter.(1)


Platelet Aggregation Patency Rate Human Blood Platelet Microvascular Surgery Improve Patency Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Acland R. Signs of patency in small vessel anastomosis. Surgery 72:744, 1972PubMedGoogle Scholar
  2. 2.
    Acland R. Thrombus formation in microvascular surgery. Surgery 73:766, 1973PubMedGoogle Scholar
  3. 3.
    Acland R: Prevention of thrombus in microvascular surgery by the use of magnesium sulphate. Br J Plast Surg 25:292, 1972PubMedCrossRefGoogle Scholar
  4. 4.
    Arfors KE: Counteraction of platelet activity at sites of laser-induced endothelial trauma. Br Med J 4:430, 1968PubMedCrossRefGoogle Scholar
  5. 5.
    Arfors KE, Dahl DP, Engeset J, et al: In vivo quantitation of platelet activity using biolaser-induced endothelial injury. 5th European Conference on Microcirculation. Bibl Anat 10:502, 1969PubMedGoogle Scholar
  6. 6.
    Ball G, Brereton G, Ireland D, et al: Effect of prostaglandin E1 alone and in combination with theophylline or aspirin on collagen-induced platelet aggregation and on platelet nucleotides including adenosine 3,5-cyclic monophosphate. Biochem J 120:709, 1970PubMedGoogle Scholar
  7. 7.
    Bergström S: Isolation structure and action of the prostaglandins. In Nobel Symposium 2, Prostaglandins. S, Sammuelson B (eds): Bergström 1967, p. 21 Stockholm.Google Scholar
  8. 8.
    Bergström S, Carlson LA, Ekelund L, et al: Cardiovascular and metabolic response to infusions of prostaglandin E1 and to simultaneous infusions of noradrenaline and prostaglandin E1 in man. Acta Physiol Scand 64:332, 1965PubMedCrossRefGoogle Scholar
  9. 9.
    Bergström S, Duner H, von Euler US, et al: Observations on the effects of infusion of prostaglandin E1 in man. Acta Physiol Scand 45:145, 1959PubMedCrossRefGoogle Scholar
  10. 10.
    Berman HJ, Tangen O, Ausprunk D: Prostaglandin E1 inhibition of aggregation of hamster platelets. 5th European Conference on Microcirculation. Bib Anat 10:507, 1969Google Scholar
  11. 11.
    Born GVR: Observations on the rapid morphological reaction of platelets to aggregating agents. Ser Haemetol 3(4): 114, 1970Google Scholar
  12. 12.
    Born GVR: Platelets in thrombogenesis. Mechanism and inhibition of platelet aggregation. Ann Coll Surg Engl 36:200, 1965Google Scholar
  13. 13.
    Boullin DJ, Green AR, Price KS: The mechanism of ADP-induced platelet aggregation binding to platelet receptors and inhibition of binding and aggregation by prostaglandin E1. J Physiol 221:415, 1972PubMedGoogle Scholar
  14. 14.
    Bousser M: Effects of combined prostaglandin E1 and aspirin on experimental arterial thrombosis in rabbits. Biomedicine 19:90, 1973PubMedGoogle Scholar
  15. 15.
    Brodie GN, Baeuziger N, Chase L: The effects of thrombin on adenyl cyclase activity and a membrane protein from human platelets. Clin Invest 51:81, 1972CrossRefGoogle Scholar
  16. 16.
    Butcher RW: Prostaglandins and cyclic-AMP. In Greengard P, Costa E (eds): Advances in Biochemical Psychopharmacology, Vol. 3. 1970, p. 173Google Scholar
  17. 17.
    Carlson LA, Ekelund L, Orö L: Clinical and metabolic effects of different doses of prostaglandin E1 in Man. Acta Med Scand 183:423, 1968PubMedCrossRefGoogle Scholar
  18. 18.
    Carlson LA, Irion E, Orö L: Effect of infusion of prostaglandin E1 on the aggregation of blood platelets in man. Life Sci 7:85, 1968PubMedCrossRefGoogle Scholar
  19. 19.
    Clausen J, Srivastava KC: The synthesis of prostaglandins in human platelets. Lipids 7(4):246, 1972PubMedCrossRefGoogle Scholar
  20. 20.
    Droller MJ, Wolfe S: Thrombin-induced increase in intracellular cyclic 3’5’-adenosine monophosphate in human platelets. J Clin Invest 51:3094, 1972PubMedCrossRefGoogle Scholar
  21. 21.
    Elkeles RS, Hampton JR, Harrison MJ: Prostaglandin E1 and human platelets. Lancet 2:111, 1969PubMedCrossRefGoogle Scholar
  22. 22.
    Emmons PR, Hampton JR, Harrison MJ, et al: Effect of prostaglandin E1 on platelet behavior in vitro and in vivo. Br Med J 2:468, 1967PubMedCrossRefGoogle Scholar
  23. 23.
    Evans G, Mustard J: Platelet-surface reaction and thrombosis. Surgery 64:273, 1968PubMedGoogle Scholar
  24. 24.
    Glenn E, Wilks J, Bowman B: Platelets, prostaglandins, red cells, sedimentation rates, serum and tissue proteins and non-steroidal anti-inflammatory drugs. Proc Soc Exp Biol Med 141:879, 1972PubMedGoogle Scholar
  25. 25.
    Grottenlos J, Hornstra G: The influence of prostaglandin E1 on experimental platelet aggregation in rats. In Jones JR (ed): Proceedings of the 2nd International Symposium on Atherosclerosis, Chicago, 1969. New York Heidelberg Berlin, Springer-Verlag, 1970Google Scholar
  26. 26.
    Hinman J: The prostaglandins. Bioscience 17:779, 1967CrossRefGoogle Scholar
  27. 27.
    Hornstra G: Degree and duration of prostaglandin E1-induced inhibition of platelet aggregation in the rat. Eur Pharmacol 15:343, 1971CrossRefGoogle Scholar
  28. 28.
    Horton EW: Hypothesis on physiological roles of prostaglandins. Physiol Rev 49:122, 1969PubMedGoogle Scholar
  29. 29.
    Horton EW: The prostaglandins. In Staey RS, Robson JM (eds): Recent Advances in Pharmacology, 4th ed. p.186Google Scholar
  30. 30.
    Irion E, Blomback M: Prostaglandins in platelet aggregation. Scand J Clin Lab Invest 24:141, 1969PubMedCrossRefGoogle Scholar
  31. 31.
    Jorgensen H, Sondergaard J: Vascular responses to prostaglandin E1. Acta Derm Vener. (Stockh) 53:203, 1973Google Scholar
  32. 32.
    Kaegi H, Pineo G, Shimizu A, et al: Arterio-venous shunt thrombosis, prevention by sulfinpyrayone. N Engl J Med 290:304, 1974PubMedCrossRefGoogle Scholar
  33. 33.
    Kaley G, Weiner R: Microcirculatory studies with prostaglandin E1. In Ramwell PW, Shaw JE (eds): Prostaglandin Symposium of the Worchester Foundation for Experimental Biology. New York, Wiley Inter-science, 1968Google Scholar
  34. 33.
    Karim SMM (ed): Prostaglandin, Progress in Research. New York, Wiley Inter-science, 1972, p 240Google Scholar
  35. 34.
    Ketchum LD, Wennen WW, Masters FW, and Robinson DW: Experimental use of pluronic F68 in microvascular surgery. Plast Re-const Surg 53:288, 1974CrossRefGoogle Scholar
  36. 35.
    Kloeze J: Influence of prostaglandins on platelet adhesives and platelet aggregation. In Bergström S, Sammuelson B(eds): Nobel Symposium 2, Prostaglandins. Stockholm, 1967, p241Google Scholar
  37. 36.
    Kloeze J: Relationship between chemical structure and platelet aggregation activity of prostaglandins. Biochem Biophys Acta 187:285, 1969PubMedGoogle Scholar
  38. 37.
    Kloeze J: Influence of prostaglandins on ADP-induced platelet aggregation. Netherlands Society for Physiology and Pharmacology Meeting, April 6, 1967Google Scholar
  39. 38.
    Kloeze J: Influence of Prostaglandins E1 and E2 on coagulation of rat blood. Experientia 26:307, 1970PubMedCrossRefGoogle Scholar
  40. 39.
    Kluge TH, et al: Thrombosis prophylaxis with dextran and warfarin in vascular operations. Surg Gynecol Obstet 135:941, 1972PubMedGoogle Scholar
  41. 40.
    Lee J, et al: Prostaglandins as therapeutic agents. Arch Intern Med 131:294, 1973PubMedCrossRefGoogle Scholar
  42. 41.
    Marquis N, Becker J, Vigdahl R: Platelet aggregation and epinepherine-induced decrease in cyclic-AMP synthesis. Biochem and Biophys Res Commun 39:783, 1970CrossRefGoogle Scholar
  43. 42.
    Marquis N, Vigdahl R, Tavorina P: Biochemical role of prostaglandin E1 in the inhibition of platelet aggregation. Second International Symposium on Atherosclerosis, Chicago, 1969Google Scholar
  44. 43.
    Marquis N, Vigdahl R, Tavorina P: Platelet aggregation regulation by cyclic-AMP and prostaglandin E1. Biochem Biophys Res Commun 36:965, 1969PubMedCrossRefGoogle Scholar
  45. 44.
    Mattila S, Fogarty T: Heterologous vascular grafts as small vessel substitutes. Annales, Chir Gynaecol Fenn 62:234, 1973Google Scholar
  46. 45.
    Mayer J, Hammond G: Dipyridamole and aspirin tested against an experimental model of thrombosis. Ann Surg 178:108, 1973PubMedCrossRefGoogle Scholar
  47. 46.
    Mills D, Smith J: The control of platelet responsiveness by agents that influence cyclic-AMP metabolism. Ann NY Acad Sci 201:391, 1972PubMedCrossRefGoogle Scholar
  48. 47.
    Mills D, Smith J: The influence of platelet aggregation of drugs that affect the accumulation of adenosine 3′,5′ cyclic monophosphate in platelets. Biochem J 121:185, 1971PubMedGoogle Scholar
  49. 48.
    Mustard J: Platelets, drugs, and Thrombosis. CMAJ 108:443, 1973Google Scholar
  50. 49.
    Mustard J, Packham M: Thromboembolism. A manifestation of the response of blood injury. Circulation 42:1, 1970PubMedGoogle Scholar
  51. 50.
    Mustard JF, Rowsell HC, Smythe HA: The effect of sulfinpyrazone on platelet economy and thrombosis formation in rabbits. Blood 29:859, 1967PubMedGoogle Scholar
  52. 51.
    Nakano T: Effects of prostaglandins E1, A1, F2 on the coronary and peripheral circulation. Proc Soc Exp Biol Med 127:1160, 1968PubMedGoogle Scholar
  53. 52.
    Nomoto H, Buncke HJ, Chater NL: Improved patency rates in microvascular surgery when using magnesium sulfate and a silicone rubber vascular cuff. Plast Reconstr Surg 54:157, 1974PubMedGoogle Scholar
  54. 53.
    O’Brien J, Henderson P, Bennett RC, Crock GW: Microvascular surgical techniques. Med J Aust 1:722, 1970PubMedGoogle Scholar
  55. 54.
    O’Brien J, Tulevski V, Etherington M, Madgwick T: Platelet function studies before and after operation and the effect of post-operative thrombosis. J Lab Clin Med 83:342 1974PubMedGoogle Scholar
  56. 55.
    Pelofsky S, Jacobson E, Fisher R: Effects of prostaglandin E1 on experimental cerebral vasospasm. J Neurosurg 36:634, 1972PubMedCrossRefGoogle Scholar
  57. 56.
    Pickles V: Prostaglandins. Nature 224:221, 1969PubMedCrossRefGoogle Scholar
  58. 57.
    Salzman E: Cyclic AMP and platelet function. N Engl J Med 286:358, 1972PubMedCrossRefGoogle Scholar
  59. 58.
    Salzman E, Levine L: Cyclic 3’,5’-adenosine monophosphate in human blood platelets. J Clin Invest 50:131, 1971PubMedCrossRefGoogle Scholar
  60. 59.
    Silver MF, et al: Human blood prostaglandins. Formation during clotting. Prostaglandins 1:429, 1972PubMedCrossRefGoogle Scholar
  61. 60.
    Smith E, McMorrow J, Covino B, et al: Studies on the vasodilator action of prostaglandin E1. In Ramwell PW, Shaw JE (eds): Prostaglandin Symposium of the Worchester Foundation for Experimental Biology. New York, Wiley Interscience 1968, p 259Google Scholar
  62. 61.
    Smith J, Ingerman C, Kocsis JJ, Silver MJ: Formation of prostaglandins during the aggregation of human blood platelets. J Clin Invest 52:965, 1973PubMedCrossRefGoogle Scholar
  63. 62.
    Smythe H, Ogryzlo MA, Murphy EA, et al: The effect of sulfinpyrazone on platelet economy and blood coagulation in man. Can Med Assoc J 92:818, 1965PubMedGoogle Scholar
  64. 63.
    Sondergaard J, Helin P, Jorgensen H: Human cutaneous inflammation induced by prostaglandin E1. J Pathol 109:239, 1973PubMedCrossRefGoogle Scholar
  65. 64.
    Steiner L, Forster D, Bergvall U, et al: Effect of prostaglandin E1 on cerebral circulatory disturbances following subarachnoid haemorrhage in man. Neuroradiology 4:409, 1972CrossRefGoogle Scholar
  66. 65.
    Tuttle R, Skelly M: Interactions of prostaglandin E1 and ouabain on Contractility of isolated rabbit atria and intracellular cation concentration. In Ramwell S, Shaw JE (eds): Prostaglandin Symposium of the Worchester Foundation for Experimental Biology. New York, Wiley Inter-science 1968, p 309Google Scholar
  67. 66.
    Van Crevald S, Pascha CN: Influence of the prostaglandins E1 and E2 on aggregation of blood platelets. Nature 218:316, 1968CrossRefGoogle Scholar
  68. 67.
    Van Crevald S, Pascha CN: Abnormality in the aggregation of blood platelets in various morbid conditions and the influence of prostaglandins upon this abnormality. Thromb Diath Haemorrh 20:180, 1968Google Scholar
  69. 68.
    Vigdahl R, Marquis N, Tavormina P: Platelet aggregation, Adenyl Cyclase, Prostaglandin E1 and Calcium. Biochem Biophys Res Commun 37:409, 1969PubMedCrossRefGoogle Scholar
  70. 69.
    Viguera M, Sunahara F: Microcirculatory effects of prostaglandins. Can J Physiol Pharmacol 47:627, 1969PubMedCrossRefGoogle Scholar
  71. 70.
    Weeks J, Sekhar N, Ducharme D: Relative activity of prostaglandins E1, A1, E2, and A2 on lipolysis, platelet aggregation, smooth muscle and the cardiovascular system. J Pharm Pharmacol 21:103, 1969PubMedCrossRefGoogle Scholar
  72. 71.
    Wolfe S, Shulman N: Adenyl cyclase activity in human platelets. Biochem Biophys Res Commun 35:266, 1969CrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1978

Authors and Affiliations

  • Roderick G. Lamond
  • Norman L. Chater

There are no affiliations available

Personalised recommendations